[Problem of restenosis inside stents with an antiproliferative coating].
The article deals with a review of clinical studies carried out within the time period from 2003 to 2007. The review contains the data concerning restenoses of sirolimus- and paclitaxel-eluting stents, suggesting that the stents with an antiproliferative coating substantially diminished the acuity of the problem regarding restenoses but did not solve the problem completely. The incidence rate of restenoses remains high in patients with diabetes mellitus as well as in those with bifurcation stenoses, acute and chronic occlusions of coronary arteries. Analysing the published data the authors made a conclusion that during angioplasty of acute and chronic occlusions of coronary arteries preference should be given to sirolimus-eluting stents since they are most effective in prevention of restenoses inside stents in such lesions. Analysing the findings of clinical trials of drug-eluting stents showed efficiency and safety of such stents in treatment of in-stent restenoses. Patients with diabetes mellitus are exceptions to this rule, being poor candidates for drug-eluting stents, since the latter proved to exhibit low efficacy in these patients.
Krylov
A L
AL
Maslov
L N
LN
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D020099:Coated Materials, Biocompatible; D006083:Graft Occlusion, Vascular; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology; D020123:Sirolimus / Q000494:pharmacology; D015607:Stents
D000900:Anti-Bacterial Agents; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus